Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Amgen and Novartis are stopping work on an experimental Alzheimer’s disease drug after an early look at clinical data showed worsening cognitive function in patients.

The interim results announced Thursday were part of a pre-planned review of data from two pivotal clinical trials testing the drug, umibecestat. Based on that review, Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS) said that they are discontinuing further development of the drug because its potential benefit does not outweigh the risks.